| Title |
Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort
|
|---|---|
| Published in |
European Archives of Psychiatry and Clinical Neuroscience, November 2017
|
| DOI | 10.1007/s00406-017-0847-1 |
| Pubmed ID | |
| Authors |
G. Fond, N. Resseguier, F. Schürhoff, O. Godin, M. Andrianarisoa, L. Brunel, E. Bulzacka, B. Aouizerate, F. Berna, D. Capdevielle, I. Chereau, T. D’Amato, C. Dubertret, J. Dubreucq, C. Faget, F. Gabayet, C. Lançon, P. M. Llorca, J. Mallet, D. Misdrahi, C. Passerieux, R. Rey, A. Schandrin, M. Urbach, P. Vidailhet, L. Boyer, M. Leboyer, the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group |
| Abstract |
Low-grade inflammation has repeatedly been associated with schizophrenia (SZ) and in particular with cognitive impairment. Female gender, overweight and tobacco smoking have been suggested as risk factors to increase inflammation while preclinical inconsistent findings have been found regarding the association with psychotropic drugs. The aim of this study was to explore if psychotropic drugs were associated with inflammation in SZ and to determine which psychotropic drug was associated with inflammation in stable SZ subjects while considering clinical confounding factors. Participants were consecutively included in the network of the FondaMental Expert Centers for Schizophrenia and received a thorough clinical assessment, including recording of current treatment. High-sensitivity CRP (hs-CRP) was measured for each participant as a proxy to define peripheral low-grade inflammation. The zero-inflated Poisson regression model estimated the relationship between low-grade inflammation and psychotropic drug. Four hundred and five stabilized, community-dwelling SZ subjects (mean age = 32.6 years, 74% male gender) have been included. In total, 148 participants (36.5%) were found with undetectable blood hs-CRP level. The probability of having an undetectable CRP was associated with a lower body mass index (p < 0.0001) and no cyamemazine add-on antipsychotic therapy (p = 0.001). The other 257 participants (63.5%) were found to have low-grade inflammation (hs-CRP > 0 mg/L). Low-grade inflammation was significantly associated with female gender (p = 0.004), higher body mass index (p < 0.0001), current tobacco smoking (p < 0.0001), clomipramine (p = 0.04), quetiapine (p < 0.0001) and hypnotic (p = 0.0006) consumption while decreased hs-CRP blood levels was associated with aripiprazole (p = 0.004) and valproate/valpromide (p = 0.03) consumption. The present study suggests that some psychotropic drugs (quetiapine, cyamemazine, clomipramine) may be associated with increased peripheral low-grade inflammation in SZ patients while others (aripiprazole, valproate) may be associated with decreased peripheral low-grade inflammation. These results should be replicated in SZ and non-SZ populations and the biological underpinnings should be further explored. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 9% |
| Ireland | 1 | 9% |
| United Kingdom | 1 | 9% |
| United States | 1 | 9% |
| Unknown | 7 | 64% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 91% |
| Scientists | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 78 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 14% |
| Student > Bachelor | 8 | 10% |
| Other | 7 | 9% |
| Student > Doctoral Student | 7 | 9% |
| Student > Ph. D. Student | 6 | 8% |
| Other | 14 | 18% |
| Unknown | 25 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 27% |
| Psychology | 6 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Neuroscience | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 34 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2018.
All research outputs
#5,910,885
of 23,815,455 outputs
Outputs from European Archives of Psychiatry and Clinical Neuroscience
#325
of 1,243 outputs
Outputs of similar age
#92,617
of 330,022 outputs
Outputs of similar age from European Archives of Psychiatry and Clinical Neuroscience
#2
of 13 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,243 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,022 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.